Metformin interferes with glucose cellular uptake by both estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cell lines

I. Amaral1, C. Silva, A. Correia-Branco, F. Martel

Aim: Transport experiments with 3H-DG, culture growth and proliferation rate assays were performed. This work aimed to investigate the possible interference of metformin with glucose uptake by MCF-7 and MDA-MB-231 human breast adenocarcinoma cell lines as a mechanism contributing to its anticarcinogenic effect.

Introduction: Breast cancer, the most common cancer among women, remains one of the leading causes of mortality among women worldwide.1 Metformin has been widely used as a treatment for type 2 diabetes for over 40 years.2 The first report of a reduced risk of developing cancer for diabetic patients treated with metformin was published in 2005.3 Several mechanisms of action of metformin appear to be implicated in this effect.2,4

Methods: Transport experiments with 3H-DG, culture growth and proliferation rate assays were performed.

Results: Acute (26 min) exposure of MCF-7 cells to metformin significantly inhibited uptake of 3H-deoxy-D-glucose (3H-DG) (maximal inhibition found with metformin 0.5 mM: 27 ± 2% reduction). Chronically (24 h), metformin induced a concentration-dependent increase in 3H-DG uptake (maximal inhibition found with metformin 1 mM: 81 ± 15% increase). Acute (26 min) exposure of MDA-MB-231 cells to metformin slightly inhibited uptake of 3H-DG (maximal inhibition found with metformin 1 mM: 10 ± 3% reduction). Chronic (24 h) exposure to metformin significantly increased 3H-DG uptake by MDA-MB-231 cells (maximal increase observed with metformin 1 mM: 30 ± 8% increase).

Chronic (24 h) exposure of both cell lines to metformin (1 mM) decreased culture growth/cell mass; in contrast, it increased cell proliferation rates. Combination of metformin (1 mM) with the facilitative glucose transporter (GLUT) inhibitor kaempferol (30 µM) did not result in a more marked effect on culture growth and cell proliferation rates.

Conclusion: Summarizing, chronic exposure of MCF-7 and MDA-MB-231 cells to metformin induces a marked increase in glucose uptake, associated with an anticarcinogenic effect of the drug. We suggest that the increase in glucose uptake is a compensatory mechanism to cellular energy depletion induced by metformin.

Acknowledgements: This study was supported by Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal (Plano estratégico UID/BIM/04293/2013).

References
Conclusion: These results suggest that cell viability loss promoted by 2-AG and AEA was associated with ER-stress since both PERK and IRE1 arms of UPR are activated. Prolonged ER-stress contributes to the expression of pro-apoptotic proteins, such as CHOP. These findings shed light to the impact of endocannabinoids induced-ER stress which may negatively affect trophoblast cell turnover and pregnancy outcomes.

Acknowledgements: This work received support from European Union (FEDER funds through COMPETE) and FCT through project PTDC/DTD-FTO/5651/2014-POCI-01-0145-FEDER-016562; FCT/MEC through national funds and co-financed by FEDER, under PT2020 (UID/01/0145/FEDER/007728) and CCDR-N/NORTE2020/Portugal 2020 (norte-01-0145-FEDER-000024).

References
http://dx.doi.org/10.1016/j.pbj.2017.07.103

PS163
Analysis of imaging characteristics, incidence, and prognosis of brain metastases from thyroid cancer
Mafalda Sampaio Alves 1-∗, Eduarda Carneiro 4, Diana Ferreira 4, Isabel Torres 3, Susana Maria Silva 2, 3, Mavilde Arantes 2, 3, 4
1 Faculty of Medicine, University of Porto, 4200-319 Porto
2 Unit of Anatomy, Department of Biomedicine, Faculty of Medicine of the University of Porto, 4200-319 Porto
3 Center for Health Technology and Services Research (CINTESIS), 4200-450 Porto, Portugal
4 Division of Neuroradiology, Radiology Service, Portuguese Institute of Oncology, Porto, Portugal
5 Endocrinology Service, Portuguese Institute of Oncology, Porto, Portugal
E-mail address: sampaiolavesm@gmail.com (M.S. Alves).

Aim: The main objectives of this study were to evaluate the incidence, imaging characteristics, and prognosis of parenchymal brain metastases originating in thyroid cancer.

Introduction: While thyroid cancer is a relatively common type of cancer, it is usually highly curable.1 Brain metastases from thyroid cancer are rare and their imaging appearance has not been well defined.2

Methods: Review of case records of thyroid cancer patients within the IPO Porto data base from 2005 to 2015 was conducted in order to identify the patients with thyroid cancer and evidence of brain metastases.

Results: We identified 3175 patients with thyroid cancer, with only five having evidence of brain metastases (two from papillary thyroid cancer, two from follicular thyroid cancer and one from poorly differentiated thyroid cancer). At the time of brain metastases detection, 100% of the patients had concurrent lymph node metastases, 80% lung metastases and 60% osseous metastases. Of those brain metastases, 60% were multifocal and 40% presented as partially cystic/necrotic. Of the two cases in which the patients died, the median overall survival after brain metastasis detection was less than one year.

Conclusion: Brain metastasis from thyroid cancer remains a rare phenomenon that most frequently occurs in the setting of widely disseminated lymph node disease. The imaging appearance is highly variable and the prognosis is poor.

References
http://dx.doi.org/10.1016/j.pbj.2017.07.104

PS166
The association of GSTP1 genotype with the risk and survival in ccRCC patients with advanced tumor stage
S. Mihailovic 1-∗, T. Radic 1, 2, M. Pljesa Ercegovac 1, 2, V. Coric 1, 2
1 Faculty of Medicine, University of Belgrade, Serbia
2 Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Serbia
E-mail address: smiljanamihailovic@gmail.com (S. Mihailovic).

Aim: The aim of this study was to evaluate specific role of glutathione S-transferase P1 (GSTP1) gene variants as determinants of ccRCC risk in patients with advanced tumor stage (pT3 and pT4). Furthermore, we evaluated the effect of GSTP1 gene variants on postoperative prognosis in these patients.

Introduction: Renal cell carcinoma (RCC) accounts for up to 90% of malignant kidney tumors with clear renal cell carcinoma (ccRCC) being the most frequent and the most aggressive subtype of sporadic RCC in adults. Unfortunately, most RCCs are asymptomatic in early stages, whereas symptomatic RCC correlates with aggressive histology and advanced disease. Aside from known risk factors for RCC, evidence suggest that the development of RCC can be partially explained by genetic variations among the populations. Highly polymorphic cytosolic glutathione S-transferases are known to be involved in both the development and the progression of renal cell carcinoma.

Methods: GSTP1 genotype was determined in 99 ccRCC patients and 326 matched-controls by qPCR method, using TaqMan® SNP Genotyping Assay. The risk for disease was computed by odds ratios (OR) and 95% confidence intervals (CI) using logistic regression analysis. Furthermore, overall survival was analyzed as well by Kaplan–Meier method and Cox proportional hazard regression model.

Results: GSTP1-variant genotype was associated with 5-fold increased risk for ccRCC in comparison with GSTP1-wild type genotype (p < 0.001). Moreover, survival analysis clearly indicated shorter overall survival in ccRCC patients with GSTP1-variant genotype, however without reaching statistical significance (p = 0.166). Additionally, ccRCC patients with GSTP1-variant genotype had a 7-fold higher hazard ratio (p = 0.177), compared to the carriers of GSTP1-wild type genotype.

Conclusion: GSTP1-variant genotype contributed independently towards the risk of ccRCC in our patients. Moreover, GSTP1-variant genotype is associated with poor postoperative prognosis in ccRCC.

http://dx.doi.org/10.1016/j.pbj.2017.07.105